(Q37724573)

22 August 2017

1 reference

title

Biomarkers and surrogate end points--the challenge of statistical validation (English)

1 reference

22 August 2017

0 references

0 references

1

Marc Buyse

0 references

Aimery de Gramont

5

object named as

Aimery de Gramont

0 references

author name string

Daniel J Sargent

2

1 reference

22 August 2017

Axel Grothey

3

1 reference

22 August 2017

Alastair Matheson

4

1 reference

22 August 2017

language of work or name

English

0 references

publication date

6 April 2010

1 reference

Nature Reviews Clinical Oncology

22 August 2017

1 reference

22 August 2017

7

1 reference

22 August 2017

6

1 reference

22 August 2017

309-317

1 reference

Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer

22 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Protein biomarker discovery and validation: the long and uncertain path to clinical utility

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Rules of evidence for cancer molecular-marker discovery and validation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Strategic paths for biomarker qualification

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Biomarker qualification pilot process at the US Food and Drug Administration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Meta-analyses of adjuvant therapies for women with early breast cancer: the Early Breast Cancer Trialists' Collaborative Group overview

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Gastrointestinal stromal tumors II: medical oncology and tumor response assessment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Targeted drugs in chronic myeloid leukemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Gene expression profiling predicts clinical outcome of breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

A gene-expression signature as a predictor of survival in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Gene-expression signatures in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Visualizing length of survival in time-to-event studies: a complement to Kaplan-Meier plots

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Sample size requirements and length of study for testing interaction in a 2 x k factorial design when time-to-failure is the outcome [corrected]

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Clinical trial designs for predictive biomarker validation: one size does not fit all.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Clinical trial designs for predictive marker validation in cancer treatment trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

The validation of surrogate endpoints in meta-analyses of randomized experiments

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Statistical evaluation of biomarkers as surrogate endpoints: a literature review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogat

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Surrogate endpoints in clinical trials: definition and operational criteria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Criteria for the validation of surrogate endpoints in randomized experiments.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

A unifying approach for surrogate marker validation based on Prentice's criteria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Individual- and trial-level surrogacy in colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Surrogate and mediating endpoints: current status and future directions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Statistical challenges in the evaluation of surrogate endpoints in randomized trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Surrogate marker evaluation from an information theory perspective

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Contributions of meta-analyses based on individual patient data to therapeutic progress in colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Endpoints and surrogate endpoints in colorectal cancer: a review of recent developments

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Progression-free survival is a surrogate for survival in advanced colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Exploring and validating surrogate endpoints in colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Assessing the measure of a new drug: is survival the only thing that matters?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Phases of biomarker development for early detection of cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

The Biomarkers Consortium: on the critical path of drug discovery.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Prognostic and predictive value of HER2/neu oncogene in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

End points in advanced colon cancer clinical trials: a review and proposal

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Surrogate endpoint validation: statistical elegance versus clinical relevance.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

The value, qualification, and regulatory use of surrogate end points in drug development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Factors predictive of response to hormone therapy in breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.43

Molecular classification of breast tumors: toward improved diagnostics and treatments

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20368727

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20368727

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2010.43

1 reference

22 August 2017

1 reference